ArticleScientific reports2025
Assessment of serum survivin in women with placenta previa and accreta spectrum: a cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survivin Expression in Placentas with Intrauterine Growth Restriction.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the relationship between maternal serum survivin levels and placental disorders by comparing these levels across cases of normal placentation, placenta previa, and placenta accreta spectrum (PAS). In this prospective cross-sectional study, we enrolled 84 pregnant women categorized into control (n = 42), placenta previa (n = 24), and PAS (n = 28) groups. Serum survivin levels were quantitatively determined using ELISA, and statistical analyses were performed using ANOVA and post-hoc tests. Serum survivin levels were significantly elevated in the placenta previa (348.3 pg/mL, range: 173.0-776.4) and PAS groups (785 pg/mL, range: 324.50-1122) compared to controls (177.9 pg/mL, range: 87.3-242.0) (p < 0.05), suggesting an association between survivin expression and abnormal placental adherence and invasion. Our findings demonstrate significant associations between elevated serum survivin levels and placental disorders, specifically placenta previa and PAS. These associations suggest a potential role for survivin in the pathogenesis of placental complications and warrant further investigation through longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.